PTC Therapeutics (PTCT) Misses Q4 EPS by 39c

PTC Therapeutics (NASDAQ: PTCT) reported Q4 EPS of ($2.03), $0.39 worse than the analyst estimate of ($1.64). Revenue for the quarter came in at $165.2 million versus the consensus estimate of $150.83 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Worried the AI trade has gone too far? Evercore likes these 4 stocks
• Credo Technology pops 3.5% as Evercore initiates with monster $325 price target